PrECOG, LLC is reporting clinical efficacy and biomarker analyses of the trial in which durvalumab, an immune checkpoint antibody targeting PD-L1, is added to pemetrexed and cisplatin (Pem-Cis), the only FDA approved regimen, in 55 patients of any histologic subtype of mesothelioma.
The study met its primary endpoint with a median overall survival (OS) of 20.4 months (one-sided P=0.0014) as compared to historical control (Vogelzang et al. J Clin Oncol 2003) of 12.1 months. OS rates at 12 and 24 months were 70....
PrECOG, LLC is reporting clinical efficacy and biomarker analyses of the trial in which durvalumab, an immune checkpoint antibody targeting PD-L1, is added to pemetrexed and cisplatin (Pem-Cis), the only FDA approved regimen, in 55 patients of any histologic subtype of mesothelioma.
The study met its primary endpoint with a median overall survival (OS) of 20.4 months (one-sided P=0.0014) as compared to historical control (Vogelzang et al. J Clin Oncol 2003) of 12.1 months. OS rates at 12 and 24 months were 70....